Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants.
Saved in:
| Title: | Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants. |
|---|---|
| Authors: | Hoch M; Novartis Biomedical Research, Basel, Switzerland. matthias.hoch@novartis.com., Taylor AJ; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Huth F; Novartis Biomedical Research, Basel, Switzerland., Jamalapuram S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Loisios-Konstantinidis I; Novartis Biomedical Research, Basel, Switzerland., Quinlan M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Kranidi A; Novartis Ireland Limited, Dublin, Ireland., Coleman D; Novartis Pharma AG, Basel, Switzerland., Espurz N; Novartis Pharma AG, Basel, Switzerland., Bellibas SE; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Pierre AS; Novartis Biomedical Research, Basel, Switzerland. |
| Source: | Clinical pharmacokinetics [Clin Pharmacokinet] 2026 May; Vol. 65 (5), pp. 709-718. Date of Electronic Publication: 2026 Mar 17. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1179-1926 |
|---|---|
| DOI: | 10.1007/s40262-026-01629-1 |
